関節リウマチtofacitinib臨床試験における心血管イベントリスク多寡の心血管イベント発生率への影響
Ann Rheum Dis. 2023;82(4):575–577 doi: 10.1136/ard-2022-223406
Data suggest that an important difference between P123LTE and ORAL Surveillance was the proportion of patients with a history of atherosclerotic CV disease (ASCVD).